Cargando…

Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)‐Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib

Tyrosine kinase inhibitors represented by sorafenib are the first‐line treatment for hepatocellular carcinoma (HCC), but the low response rate of HCC patient has become a clinical pain‐point. Emerging evidences have revealed that metabolic reprogramming plays an important role in regulating the sens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Senlin, Xu, Lei, Wu, Guo, Huang, Ziqi, Huang, Linzhuo, Zhang, Fengqian, Wei, Chunfang, Shen, Qian, Li, Rong, Zhang, Lei, Xu, Xiaoding
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323624/ https://www.ncbi.nlm.nih.gov/pubmed/37203277 http://dx.doi.org/10.1002/advs.202207118

Ejemplares similares

Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer
por: Li, Senlin, et al.
Publicado: (2023)

Charge-Mediated Co-assembly of Amphiphilic Peptide and Antibiotics Into Supramolecular Hydrogel With Antibacterial Activity
por: Xu, Lei, et al.
Publicado: (2020)

Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy
por: Dong, Zhihui, et al.
Publicado: (2023)

Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy
por: Liu, Xiaodi, et al.
Publicado: (2023)

Nanoparticles (NPs)-mediated lncBCMA silencing to promote eEF1A1 ubiquitination and suppress breast cancer growth and metastasis
por: Yang, Ke, et al.
Publicado: (2023)

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
por: Zhu, Qiankun, et al.
Publicado: (2020)

Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis
por: Shen, Qian, et al.
Publicado: (2022)

Sum Rules in the CFL Phase of QCD at finite density
por: Manuel, Cristina, et al.
Publicado: (2000)

Matricellular protein Cfl1 regulates cell differentiation
por: Tian, Xiuyun, et al.
Publicado: (2013)

Genetic CFL: Hyperparameter Optimization in Clustered Federated Learning
por: Agrawal, Shaashwat, et al.
Publicado: (2021)

Nanocarrier-mediated antioxidant delivery for liver diseases
por: Li, Senlin, et al.
Publicado: (2020)

Nanoparticles (NPs)‐Meditated LncRNA AFAP1‐AS1 Silencing to Block Wnt/β‐Catenin Signaling Pathway for Synergistic Reversal of Radioresistance and Effective Cancer Radiotherapy
por: Bi, Zhuofei, et al.
Publicado: (2020)

Masses of the Goldstone modes in the CFL phase of QCD at finite density
por: Manuel, C, et al.
Publicado: (2000)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
por: Ding, Bisha, et al.
Publicado: (2021)

Nano-pesticidal potential of Cassia fistula (L.) leaf synthesized silver nanoparticles (Ag@CfL-NPs): Deciphering the phytopathogenic inhibition and growth augmentation in Solanum lycopersicum (L.)
por: Danish, Mohammad, et al.
Publicado: (2022)

Sorafenib/2800Z Co-Loaded into Cholesterol and PEG Grafted Polylysine NPs for Liver Cancer Treatment
por: Zhang, Chen, et al.
Publicado: (2023)

Cytochalasins from Xylaria sp. CFL5, an Endophytic Fungus of Cephalotaxus fortunei
por: Ma, Kai-Liang, et al.
Publicado: (2020)

Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib
por: Chen, Zhuo, et al.
Publicado: (2018)

Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis
por: Li, Yan, et al.
Publicado: (2023)

TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC
por: Sun, Huimin, et al.
Publicado: (2022)

Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
por: Zhang, Er-lei, et al.
Publicado: (2020)

Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells
por: Luo, Lifang, et al.
Publicado: (2018)

Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
por: Zhuang, Lei, et al.
Publicado: (2017)

The Courant–Friedrichs–Lewy (CFL) Condition: 80 Years After Its Discovery
por: Moura, Carlos, et al.
Publicado: (2013)

Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy
por: Li, Jun, et al.
Publicado: (2018)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance
por: Wang, Lingxiang, et al.
Publicado: (2018)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma
por: Zheng, Ruiqi, et al.
Publicado: (2023)

Exploring Orthographic Representation in Chinese Handwriting: A Mega-Study Based on a Pedagogical Corpus of CFL Learners
por: Zhang, Jun
Publicado: (2022)

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
por: Chen, Jinbin, et al.
Publicado: (2018)

Circ_0006404 Accelerates Prostate Cancer Progression Through Regulating miR-1299/CFL2 Signaling
por: Li, Peihuan, et al.
Publicado: (2021)

Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma
por: Wang, Lei, et al.
Publicado: (2022)

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib
por: Yang, Zelong, et al.
Publicado: (2019)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
por: Li, Xuguang, et al.
Publicado: (2020)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Ma, Yongfang, et al.
Publicado: (2021)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
por: Chen, Bowen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h1st0nl2rpol31tm3n5rkac2eh